Publication date: 28/09/2017
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, announced today that THR-687 pre-clinical data will be presented at the European Association for Vision and Eye Research (EVER) 20th Annual Meeting, which is being held in Nice, France, from September 27-30th.
The poster presentation 'THR-687, a potent small molecule integrin receptor antagonist, holds promise as a therapeutic approach for back-of-the-eye vascular pathologies' provides further pre-clinical evidence supporting the development of THR-687. The presentation will take place at 15:00 CEST, Friday 29th September in the poster area.
The study to be presented evaluates the integrin-blocking capacity and anti-angiogenic properties of THR-687, a novel small molecule pan RGD integrin antagonist, under development to treat a broad range of patients with diabetic retinopathy (DR), with or without diabetic macular edema (DME).
Dr. Patrik De Haes, MD, CEO of ThromboGenics NV said,
"We are pleased to have this opportunity to present these pre-clinical data on THR-687 at the EVER meeting. THR-687 is one of 4 novel compounds we are developing for treatment of diabetic eye disease. The encouraging preclinical data we are presenting highlight our progress with THR-687 which is on track to enter the clinic in H1 2018."
Last week, ThromboGenics announced that it regained the full global rights to JETREA® from Alcon, a Novartis company, based on a mutual agreement that the unique characteristics of JETREA make Thrombogenics a better fit for building a sustainable long-term business. Under the terms of the agreement, ThromboGenics received a cash amount of €53.7 million and a forthcoming Novartis equity investment of €10 million in ThromboGenics capital.
ThromboGenics now has over €120 million in cash, which will be used to progress its pipeline of novel and unique disease modifying medicines for the treatment of diabetic eye disease.
ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for eye disease, with a focus on diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.
ThromboGenics is conducting a Phase IIa clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopathy (NPDR).
ThromboGenics is conducting a Phase II clinical study evaluating THR- 317, a PLGF inhibitor for the treatment of diabetic macular edema, as a stand-alone or as a combination therapy with anti-VEGF treatments. In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos, are in late stage pre-clinical development.
ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of symptomatic vitreomacular traction in 54 countries worldwide.
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com